Profil
Kean Meng Toh is currently Executive Director, Chief Scientific Officer & VP at CK Life Sciences International (Holdings), Inc. since 2018 and Director at Dogwood Therapeutics, Inc. since 2024.
Formerly, Dr. Toh was Director at Virios Therapeutics, Inc. Education includes undergraduate and doctorate degrees from the National University of Singapore and a graduate degree from the University of London.
Aktive Positionen von Kean Meng Toh
| Unternehmen | Position | Beginn |
|---|---|---|
| CK LIFE SCIENCES INT'L., (HOLDINGS) INC. | Technik-/Wissenschafts-/F&E-Leiter | 15.11.2018 |
Ehemalige bekannte Positionen von Kean Meng Toh
| Unternehmen | Position | Ende |
|---|---|---|
Virios Therapeutics, Inc.
Virios Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for fibromyalgia and other related conditions | Direktor/Vorstandsmitglied | - |
Ausbildung von Kean Meng Toh
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Virios Therapeutics, Inc.
Virios Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for fibromyalgia and other related conditions | Health Technology |
CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings), Inc. Pharmaceuticals: OtherHealth Technology Manufactures and markets pharmaceuticals, agriculture and nutraceuticals products | Health Technology |
National University of Singapore
National University of Singapore Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of London
University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















